Mankind Pharma Limited (NSE:MANKIND) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

The quarterly results for Mankind Pharma Limited (NSE:MANKIND) were released last week, making it a good time to revisit its performance. Results were roughly in line with estimates, with revenues of ₹36b and statutory earnings per share of ₹10.60. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Following the latest results, Mankind Pharma's 15 analysts are now forecasting revenues of ₹147.9b in 2026. This would be a decent 15% improvement in revenue compared to the last 12 months. Per-share earnings are expected to swell 10% to ₹50.59. In the lead-up to this report, the analysts had been modelling revenues of ₹148.1b and earnings per share (EPS) of ₹50.40 in 2026. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

View our latest analysis for Mankind Pharma

The analysts reconfirmed their price target of ₹2,764, showing that the business is executing well and in line with expectations. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic Mankind Pharma analyst has a price target of ₹3,300 per share, while the most pessimistic values it at ₹2,150. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.

Of course, another way to look at these forecasts is to place them into context against the industry itself. The period to the end of 2026 brings more of the same, according to the analysts, with revenue forecast to display 20% growth on an annualised basis. That is in line with its 21% annual growth over the past year. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 10% annually. So although Mankind Pharma is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. The consensus price target held steady at ₹2,764, with the latest estimates not enough to have an impact on their price targets.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for Mankind Pharma going out to 2028, and you can see them free on our platform here.

Before you take the next step you should know about the 1 warning sign for Mankind Pharma that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.